sales and revenue examples, page-11

Wee bit in this Seeking Alpha story where Scott Power from RBS is interviewed

"SP: QRxPharma Ltd. (QRXPF.PK) has a pain product that combines oxycodone and morphine. It's been through a series of clinical trials. It was knocked back at a new drug application [NDA] meeting in July this year when the U.S. Food and Drug Administration [FDA] issued a complete response letter for additional information. The company is reworking some of the data that it provided to the FDA. We are looking for a new approval date in mid-2013.

TLSR: What is the market for this product? Oncology?

SP: No, the market is postsurgical acute pain-bunionectomies, hip and knee replacements. Assuming it gets approval next year, the drug will be distributed in the U.S. Its marketing partner is Actavis Inc., which has been taken over by Watson Pharmaceuticals Inc. (WPI). Watson will distribute the product in the U.S."


http://seekingalpha.com/article/991321-analyst-scott-power-finds-the-upside-in-biotech-down-under